PRT060128

PRT060128 · Portola Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PRT060128, covering 2023-08-08 to 2023-08-08. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI [Phase 2]

See pricing